This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

Siddharth Mane
/ Categories: Trending, Mindshare
This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option.

Laurus Labs primarily focuses on providing an extensive and comprehensive range of Active Pharmaceutical Ingredients (API), which encompasses intermediates, Generic Finished Dosage Forms (FDF) and contract research services. These offerings are designed to meet the diverse requirements of the global pharmaceutical industry. 

On May 31, 2023, Laurus Labs signed an investment agreement with ImmunoACT, acquiring an additional 7.24 per cent stake for approximately Rs 80 crore. Promoters and senior management of Laurus Labs will also acquire a 0.54 per cent stake for about Rs 4 crore. Previously, Laurus Labs acquired a 26.62 per cent stake in ImmunoACT. Following this investment, Laurus Labs' shareholding in ImmunoACT will reach 33.86 per cent. 

 

DSIJ offers a product 'Mid Bridge' with recommendations for Mid-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the product details pdf here

 

Laurus Labs' additional investment in ImmunoACT will enhance its position in the emerging field of research, particularly in CAR-T therapy. CAR-T therapy has shown significant success in the western world as a promising treatment option. However, this innovative technology is currently unavailable in India. Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option. 

On Thursday, shares of Laurus Labs surged by 3.77 per cent and made an intraday high of Rs 345. It had a spurt in volume by more than 1.5 times. 

The company delivered exceptional returns of 251 per cent over the past 3 years, while over the past 5 years, it provided remarkable returns of 242 per cent. 

Investors should keep a close eye on this trending stock.

Rate this article:
3.3

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary21-Sep, 2023

IPO Analysis21-Sep, 2023

Mindshare21-Sep, 2023

IPO21-Sep, 2023

Penny Stocks21-Sep, 2023

Knowledge

Tax Column21-Sep, 2023

Tax Column

Tax Column

I am an individual and in service with a corporate organisation. In FY 2021-22, I joined a MNC that paid...

General19-Sep, 2023

Technical17-Sep, 2023

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Investment in securities market are subject to market risks.Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.